Description: Cynata Therapeutics Limited is a stem cell and regenerative medicine company. The Company is engaged in the development and commercialization of a mesenchymal stem cell (MSC) technology for human therapeutic use, Cymerus. Its Cymerus technology facilitates manufacture of MSCs from a single donor and a single donation. The Company's Cymerus platform stem cell technology is based upon stem cells known as mesenchymoangioblasts (MCAs). The Company's technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product. The Cymerus platform provides a source of MSCs that is independent of donor limitations and provides an off-the-shelf stem cell platform for therapeutic product use. The Company's MSCs produced using Cymerus technology, can be used to treat unrelated patients, without any need to match the recipient to the donor.
Home Page: www.cynata.com
CYP Technical Analysis
100 Cubitt Street
Cremorne,
VIC
3121
Australia
Phone:
61 3 7067 6940
Officers
| Name | Title |
|---|---|
| Dr. Ross Alexander MacDonald Ph.D. | MD, CEO & Exec. Director |
| Dr. Kilian Kelly | Chief Operating Officer |
| Dr. Jolanta Airey | Chief Medical Officer |
| Dr. Suzanne Lipe | VP of Alliance Management |
| Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD | Company Sec. |
Exchange: AU
Country: AU : Australia
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.764 |
| Price-to-Sales TTM: | 5.716 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |